ConvaTec Group PLC 26.7% potential upside indicated by Barclays

ConvaTec Group PLC with ticker (LON:CTEC) now has a potential upside of 26.7% according to Barclays.



Barclays set a target price of 285 GBX for the company, which when compared to the ConvaTec Group PLC share price of 209 GBX at opening today (14/06/2022) indicates a potential upside of 26.7%. Trading has ranged between 165 (52 week low) and 265 (52 week high) with an average of 4,530,627 shares exchanging hands daily. The market capitalisation at the time of writing is £4,212,289,799.

ConvaTec Group Plc is a medical product and technology company. The Company focuses on therapies for the management of chronic conditions, including products used for advanced chronic and acute wound care, ostomy care, continence and critical care and infusion devices used in the treatment of diabetes and other conditions. It provides InnovaMatrixAC and InnovaBurn. It markets and sell its solutions and services in four categories, such as Advanced Wound Care, Ostomy Care, Continence and Critical Care, and Infusion Care. Its Advanced Wound Care (AWC) is an Advanced dressing for the management of acute and chronic wounds resulting from ongoing conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. Its Ostomy Care provides devices, accessories and services for people with a stoma (a surgically created opening where bodily waste is discharged), commonly resulting from causes such as colorectal cancer, inflammatory bowel disease and bladder cancer.